XIAP (X-linked Inhibitor of Apoptosis Protein, X-linked IAP, API3, Baculoviral IAP Repeat-containing Protein 4, BIRC4, E3 Ubiquitin-protein Ligase XIAP, FLJ26913, IAP-like Protein, ILP, hILP, ILP1, Inhibitor of Apoptosis Protein 3, IAP3, IAP-3, hIAP3, hIA

XIAP [human X-linked IAP, hILP (human IAP-like protein), MIHA, BIRC4) is a member of the family of inhibitor of apoptosis proteins (IAP). IAPs suppress mitochondria-dependent and -independent apoptosis by binding to and inhibiting caspases through their BIR domains (reviewed in Liston et al, 2003; Wright and Duckett, 2005). Resistance towards apoptosis is a hallmark of cancer cells, and overexpression of IAPs can contribute to the development of cancer though inhibiting apoptosis. In addition to at least one BIR domain, some IAP members also have a RING-type finger motif at their carboxyl-terminal. The RING finger domain of several IAPs, including XIAP, have E3 ubiquitin ligase activity and target the degradation of Smac/DIABLO through ubqiuitination (Morizane et al, 2005). Smac/DIABLO is a death inducer and functions by inhibiting IAP-caspase interactions, thereby promoting apoptosis. Degradation of cell death inducers like Smac/DIABLO is thought to be a conserved mechanism by which IAPs enhance their anti-apoptotic activity, thereby promoting cell survival. XIAP is highly characterized with respect to its structure and biochemical mechanisms, and has received interest as a therapeutic target (reviewed in Schimmer, 2006). Since XIAP blocks a substantial portion of the apoptosis pathway and is associated with chemoresistance in cancer cells, inhibiting XIAP has been a focus for potential therapeutics. Approaches have included antisense oligonucleotides and small molecule inhibitors. Small molecules that that target the BIR2 and BIR3 domains of XIAP are considered particularly attractive. This is because the BIR domains inhibit caspase activity, and it is thought that removing the inhibition should increase the cell's ability to undergo apoptosis as well as decrease its potential for chemoresistance. Recognizes XIAP. Full-length human XIAP is a 497aa protein and migrates at ~53kD on SDS-PAGE.\n\nApplications:\nSuitable for use in Western Blot, Immunohistochemistry and Immunoprecipitation. Other applications not tested.\n\nRecommended Dilution:\nWestern Blot: 1:1000-1:2000\nImmunohistochemistry (formalin fixed paraffin embedded): 1:1000-1:5000\nImmunoprecipitation: 1:50-1:200\nImmunohistochemistry: Frozen\nOptimal dilutions to be determined by the researcher.\n\nPositive Control:\nSpleen, lymphatic tissues, prostate, colon, many cancer cell lines\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

X1033-98

Size

50ul

Applications

IHC, IP, WB

Hosts

Rabbit

Reactivities

Hum, Mouse, Rat

Form

Supplied as a liquid, 0.05% sodium azide.

P Type

Pab

Purity

Serum

Isotype

IgG

References

1. Deveraux QL, E Leo, HR Stennicke, K Welsh, GS Salvesen, and JC Reed. 1999. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO 18:5242-5251. 2. Wright CW and CS Duckett. 2005. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Investigation. 115:2673-2678. 3. Liston P, WG Fong and RG Korneluk. 2003. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene. 22:8568-8580. 4. Morizane Y, R Honda, K Fukami, and H Yasuda. 2005. X-linked inhibitor of apoptosis functions as ubiquitin ligase toward matere caspase-0 and cytosolic Smac/DIABLO. J. Biochem. 137:125-132. 5. Schimmer AD, S Dalili, RA Batey and SJ Riedl. 2006. Targeting XIAP for the treatment of malignancy. Cell Death Differentiation. 13:179-188.

Additional Info

Recognizes human XIAP. Species Crossreactivity: gerbil, mouse, rat.

Alternative Names

EC=6.3.2.-